BioRestorative Therapies Inc
biorestorative.comWhat Do They Do?
Sells a cell-based cosmetic serum and develops adult stem-cell treatments for disc and spine conditions and metabolic disorders. Its planned therapies are intended for physicians and other health care professionals.
10-K for FY2025, filed Mar 26, 2026Disc/Spine Program (brtxDisc). Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own)…View ↗
Metabolic Program (ThermoStem). We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown…View ↗
BioCosmeceuticals: We operate a commercial biocosmeceutical platform. Our current commercial product, formulated and manufactured using our…View ↗
Upon regulatory approval, our cell product candidates are intended to be marketed to physicians, other health care professionals…View ↗
How Do They Make Money?
The company sells cosmetic products in one-time sales; it earns royalties when licensees make underlying sales using its intellectual property.
10-K for FY2025, filed Mar 26, 2026For each of the years ended December 31, 2025 and 2024, we generated $300,000 of cosmetic product sales revenue in connection with our…View ↗
Product sales - Revenue is recognized at the point in time the customer obtains control of the goods and the Company satisfies its…View ↗
Royalty revenue - Revenue is recognized as a usage-based royalty from customers’ usage of intellectual property pursuant to a license…View ↗
-
10-K for FY2025, filed Mar 26, 2026
FY2025 revenue by product or service ↗
$359.7K
-
10-K for FY2025, filed Mar 26, 2026
$359.7K ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product
Sold outright
10-K for FY2025, filed Mar 26, 2026 |
83% |
Product, FY2025
$300K Sources
|
Sold outright |
|
Royalty
Licensed
10-K for FY2025, filed Mar 26, 2026 |
17% |
Royalty, FY2025
$59.7K Sources
|
Licensed |
Who Are Their Customers?
Cartessa Aesthetics buys cosmetic products under a supply agreement; a separate customer generates royalty revenue under a sublicense agreement.
10-K for FY2025, filed Mar 26, 2026
Do Revenues Turn Into Profits?
No. It lost $14.2M in FY2025.
10-K for FY2025, filed Mar 26, 2026
−$15.6MView ↗
10-K for FY2025, filed Mar 26, 2026
−$14.2MView ↗
10-K for FY2025, filed Mar 26, 2026
−$10.9MView ↗
How Are They Changing?
10-Q for Q1 FY2026, filed May 14, 2026
Open tableView ↗
-
Sep 2, 2026
Company changed auditors as interim CEO and CFO stepped aside
CBIZ was dismissed and Bush & Associates CPA engaged; Katharyn Field stepped aside as interim CEO and CFO.
Sources
8-K, filed Sep 2, 2026
On August 28, 2026, BioRestorative Therapies, Inc. (the “Company”) dismissed CBIZ CPAs P.C. (“CBIZ”) as the Company’s independent…View ↗
-
Aug 25, 2026
Nasdaq issued a delinquency notice over a late quarterly report
The notice had no immediate effect on the listing; the company had until October 20, 2026, to submit a compliance plan.
Sources
8-K, filed Aug 25, 2026
As indicated in the Notice, the Company has until October 20, 2026, to submit a plan to regain compliance. If Nasdaq accepts the Company’s…View ↗
-
Aug 14, 2026
Company suspended cosmetic-product orders and shipments
The suspension is pending business review and regulatory assessment; the company has not decided to discontinue the product lines.
Sources
8-K, filed Aug 14, 2026
On August 7, 2026, BioRestorative Therapies, Inc. (the “Company”) suspended, effective immediately, all orders and shipments of its…View ↗
Growing. Revenue grew 7.8x in 4 years, from $46K in FY2021 to $359.7K in FY2025, about 67% a year.
Commercial aesthetics
The older report focused on disc/spine and metabolic therapies; the latest report also describes a commercial biocosmeceutical platform selling a cell-based serum.
10-K for FY2022, filed Mar 27, 2023 10-K for FY2025, filed Mar 26, 2026We develop therapeutic products, using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described…View ↗
BioCosmeceuticals: We operate a commercial biocosmeceutical platform. Our current commercial product, formulated and manufactured using our…View ↗
ThermoStem product approach
The older report described brown-fat-derived stem cells to generate brown adipose tissue; the latest report also describes exosomes secreted by those cells as part of the program.
10-K for FY2022, filed Mar 27, 2023 10-K for FY2025, filed Mar 26, 2026Metabolic Program (ThermoStem). We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown…View ↗
Metabolic Program (ThermoStem). We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown…View ↗
Who Do They Compete With?
Competes with Mesoblast, Fibrogenesis, DiscGenics, Isto Biologics, Novo Nordisk, Sanofi, Merck, Eli Lilly, Roche, Pfizer, Regeneron, and Altimmune
10-K for FY2025, filed Mar 26, 2026Companies working in the area of regenerative medicine with regard to the disc and spine include, among others, Mesoblast, Fibrogenesis…View ↗
Loading...
